{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:48:22Z","timestamp":1794278902452,"version":"4.9.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of University and Research","award":["PRIN 2022 - COD. 2022XF7YYL_02"],"award-info":[{"award-number":["PRIN 2022 - COD. 2022XF7YYL_02"]}]},{"name":"NEXTGENERATIONEU (NGEU) and funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan","award":["project MNESYS (PE0000006) \u2013 A Multiscale integrated approach to the study of the nervous system in health and disease"],"award-info":[{"award-number":["project MNESYS (PE0000006) \u2013 A Multiscale integrated approach to the study of the nervous system in health and disease"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01306-x","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:34:43Z","timestamp":1772584483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ultra-performance liquid chromatography\u2013mass spectrometry analysis of post-mortem brain tissue reveals specific amino acid profile dysregulation in Parkinson\u2019s disease and Alzheimer\u2019s disease patients"],"prefix":"10.1038","volume":"12","author":[{"given":"Jacopo","family":"Gervasoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Cicchinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ciasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Thiolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Urbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Errico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Usiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2666-7568(24)00094-1","volume":"5","author":"J Zhu","year":"2024","unstructured":"Zhu, J. et al. Temporal trends in the prevalence of Parkinson\u2019s disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev. 5, e464\u2013e479 (2024).","journal-title":"Lancet Healthy Longev."},{"key":"1306_CR2","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/mds.27115","volume":"32","author":"JA Obeso","year":"2017","unstructured":"Obeso, J. A. et al. Past, present, and future of Parkinson\u2019s disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov. Disord. 32, 1264\u20131310 (2017).","journal-title":"Mov. Disord."},{"key":"1306_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00702-023-02635-4","volume":"130","author":"U W\u00fcllner","year":"2023","unstructured":"W\u00fcllner, U. et al. The heterogeneity of Parkinson\u2019s disease. J. Neural Transm. 130, 827\u2013838 (2023).","journal-title":"J. Neural Transm."},{"key":"1306_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejn.14094","volume":"49","author":"JC Greenland","year":"2019","unstructured":"Greenland, J. C., Williams-Gray, C. H. & Barker, R. A. The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications. Eur. J. Neurosci. 49, 328\u2013338 (2019).","journal-title":"Eur. J. Neurosci."},{"key":"1306_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00702-019-02001-3","volume":"126","author":"R Yilmaz","year":"2019","unstructured":"Yilmaz, R., Hopfner, F., van Eimeren, T. & Berg, D. Biomarkers of Parkinson\u2019s disease: 20 years later. J. Neural Transm. 126, 803\u2013813 (2019).","journal-title":"J. Neural Transm."},{"key":"1306_CR6","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.bionps.2023.100074","volume":"9","author":"KY Yamashita","year":"2023","unstructured":"Yamashita, K. Y., Bhoopatiraju, S., Silverglate, B. D. & Grossberg, G. T. Biomarkers in Parkinson\u2019s disease: a state of the art review. Biomark. Neuropsychiatry 9, 100074 (2023).","journal-title":"Biomark. Neuropsychiatry"},{"key":"1306_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/metabo7030042","volume":"7","author":"JF Havelund","year":"2017","unstructured":"Havelund, J. F., Heegaard, N. H. H., F\u00e6rgeman, N. J. K. & Gramsbergen, J. B. Biomarker research in Parkinson\u2019s disease using metabolite profiling. Metabolites 7, 42 (2017).","journal-title":"Metabolites"},{"key":"1306_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12035-021-02657-7","volume":"59","author":"X Li","year":"2022","unstructured":"Li, X., Fan, X., Yang, H. & Liu, Y. Review of metabolomics-based biomarker research for Parkinson\u2019s disease. Mol. Neurobiol. 59, 1041\u20131057 (2022).","journal-title":"Mol. Neurobiol."},{"key":"1306_CR9","doi-asserted-by":"publisher","first-page":"106698","DOI":"10.1016\/j.nbd.2024.106698","volume":"202","author":"F Carrillo","year":"2024","unstructured":"Carrillo, F. et al. Multiomics approach discloses lipids and metabolites profiles associated to Parkinson\u2019s disease stages and applied therapies. Neurobiol. Dis. 202, 106698 (2024).","journal-title":"Neurobiol. Dis."},{"key":"1306_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41531-021-00216-4","volume":"7","author":"C Gonzalez-Riano","year":"2021","unstructured":"Gonzalez-Riano, C. et al. Prognostic biomarkers of Parkinson\u2019s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach. Npj Parkinsons Dis. 7, 73 (2021).","journal-title":"Npj Parkinsons Dis."},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnmol.2020.00080","volume":"13","author":"L Hu","year":"2020","unstructured":"Hu, L. et al. Integrated metabolomics and proteomics analysis reveals plasma lipid metabolic disturbance in patients with Parkinson\u2019s disease. Front. Mol. Neurosci. 13, 80 (2020).","journal-title":"Front. Mol. Neurosci."},{"key":"1306_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41531-021-00274-8","volume":"8","author":"G Meoni","year":"2022","unstructured":"Meoni, G. et al. Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson\u2019s disease patients. Npj Parkinsons Dis. 8, 14 (2022).","journal-title":"Npj Parkinsons Dis."},{"key":"1306_CR13","doi-asserted-by":"crossref","unstructured":"Trupp, M. et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson\u2019s disease. J. Parkinsons Dis. 4, 549\u2013560 (2014).","DOI":"10.3233\/JPD-140389"},{"key":"1306_CR14","doi-asserted-by":"crossref","unstructured":"Gervasoni, J. et al. Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson\u2019s disease patients. Npj Parkinsons Dis. 11, 274 (2025).","DOI":"10.1038\/s41531-025-01126-5"},{"key":"1306_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10072-019-04143-4","volume":"41","author":"S Kumari","year":"2020","unstructured":"Kumari, S. et al. Quantitative metabolomics of saliva using proton NMR spectroscopy in patients with Parkinson\u2019s disease and healthy controls. Neurol. Sci. 41, 1201\u20131210 (2020).","journal-title":"Neurol. Sci."},{"key":"1306_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, 4 (2021).","journal-title":"Mol. Neurodegener."},{"key":"1306_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/brain\/awm304","volume":"131","author":"M Bogdanov","year":"2008","unstructured":"Bogdanov, M. et al. Metabolomic profiling to develop blood biomarkers for Parkinson\u2019s disease. Brain 131, 389\u2013396 (2008).","journal-title":"Brain"},{"key":"1306_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/jnc.14774","volume":"150","author":"W Huang","year":"2019","unstructured":"Huang, W. et al. Metabolomics-driven identification of adenosine deaminase as therapeutic target in a mouse model of Parkinson\u2019s disease. J. Neurochem. 150, 282\u2013295 (2019).","journal-title":"J. Neurochem."},{"key":"1306_CR19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.0000000000003663","volume":"88","author":"PA LeWitt","year":"2017","unstructured":"LeWitt, P. A., Li, J., Lu, M., Guo, L. & Auinger, P. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology 88, 862\u2013869 (2017).","journal-title":"Neurology"},{"key":"1306_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/cells11030395","volume":"11","author":"K-H Chang","year":"2022","unstructured":"Chang, K.-H. et al. Alterations of sphingolipid and phospholipid pathways and ornithine level in the plasma as biomarkers of Parkinson\u2019s disease. Cells 11, 395 (2022).","journal-title":"Cells"},{"key":"1306_CR21","doi-asserted-by":"publisher","first-page":"106203","DOI":"10.1016\/j.nbd.2023.106203","volume":"184","author":"A Di Maio","year":"2023","unstructured":"Di Maio, A. et al. Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson\u2019s disease patients. Neurobiol. Dis. 184, 106203 (2023).","journal-title":"Neurobiol. Dis."},{"key":"1306_CR22","doi-asserted-by":"publisher","first-page":"106413","DOI":"10.1016\/j.nbd.2024.106413","volume":"192","author":"A Imarisio","year":"2024","unstructured":"Imarisio, A. et al. Blood D-serine levels correlate with aging and dopaminergic treatment in Parkinson\u2019s disease. Neurobiol. Dis. 192, 106413 (2024).","journal-title":"Neurobiol. Dis."},{"key":"1306_CR23","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/ene.14470","volume":"27","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2020","unstructured":"Jim\u00e9nez-Jim\u00e9nez, F. J., Alonso-Navarro, H., Garc\u00eda-Mart\u00edn, E. & Ag\u00fandez, J. A. G. Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson\u2019s disease: review and meta-analysis. Eur. J. Neurol. 27, 2336\u20132347 (2020).","journal-title":"Eur. J. Neurol."},{"key":"1306_CR24","doi-asserted-by":"crossref","unstructured":"Figura, M. et al. Serum amino acid profile in patients with Parkinson\u2019s disease. PLoS ONE 13, e0191670 (2018).","DOI":"10.1371\/journal.pone.0191670"},{"key":"1306_CR25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/ph14090935","volume":"14","author":"S Plewa","year":"2021","unstructured":"Plewa, S. et al. The metabolomic approach reveals the alteration in human serum and cerebrospinal fluid composition in Parkinson\u2019s disease patients. Pharmaceuticals 14, 935 (2021).","journal-title":"Pharmaceuticals"},{"key":"1306_CR26","doi-asserted-by":"publisher","first-page":"147118","DOI":"10.1016\/j.brainres.2020.147118","volume":"1748","author":"B Toczylowska","year":"2020","unstructured":"Toczylowska, B., Zieminska, E., Micha\u0142owska, M., Chalimoniuk, M. & Fiszer, U. Changes in the metabolic profiles of the serum and putamen in Parkinson\u2019s disease patients \u2013 in vitro and in vivo NMR spectroscopy studies. Brain Res. 1748, 147118 (2020).","journal-title":"Brain Res."},{"key":"1306_CR27","doi-asserted-by":"publisher","unstructured":"Yahyavi, I. et al. Differences in sex and genetic status affect the disruption of NMDAR-related amino acid homeostasis in Parkinson\u2019s disease. Preprint at https:\/\/doi.org\/10.1101\/2025.08.08.25333287 (2025).","DOI":"10.1101\/2025.08.08.25333287"},{"key":"1306_CR28","doi-asserted-by":"publisher","first-page":"107150","DOI":"10.1016\/j.nbd.2025.107150","volume":"216","author":"T Nuzzo","year":"2025","unstructured":"Nuzzo, T. et al. Deep brain stimulation rescues the homeostasis disruption of circulating D- and L-amino acids level in men with Parkinson\u2019s disease. Neurobiol. Dis. 216, 107150 (2025).","journal-title":"Neurobiol. Dis."},{"key":"1306_CR29","doi-asserted-by":"publisher","unstructured":"Marino, C. et al. Untargeted 1H NMR-based metabolomics reveal sex-based differences in blood metabolome profiles among patients with Parkinson\u2019s disease, regardless of their idiopathic or genetic subtype. Preprint at https:\/\/doi.org\/10.1101\/2025.10.30.25339159 (2025).","DOI":"10.1101\/2025.10.30.25339159"},{"key":"1306_CR30","doi-asserted-by":"publisher","unstructured":"Marino, C. et al. Untargeted 1H NMR-based metabolomics and high-pressure liquid chromatography analysis reveal sexual dimorphism in the serum metabolic profiles of Parkinson\u2019s disease patients harbouring rare genetic variants. Preprint at https:\/\/doi.org\/10.1101\/2025.11.20.25340670 (2025).","DOI":"10.1101\/2025.11.20.25340670"},{"key":"1306_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19709-x","volume":"24","author":"H Peng","year":"2024","unstructured":"Peng, H. et al. Association between kidney function and Parkinson\u2019s disease risk: a prospective study from the UK Biobank. BMC Public Health 24, 2225 (2024).","journal-title":"BMC Public Health"},{"key":"1306_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40478-021-01136-3","volume":"9","author":"JF Reyes","year":"2021","unstructured":"Reyes, J. F. et al. Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson\u2019s disease. Acta Neuropathol. Commun. 9, 46 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1306_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-024-00732-z","volume":"10","author":"X Luo","year":"2024","unstructured":"Luo, X., Liu, Y., Balck, A., Klein, C. & Fleming, R. M. T. Identification of metabolites reproducibly associated with Parkinson\u2019s Disease via meta-analysis and computational modelling. Npj Parkinsons Dis. 10, 1\u201317 (2024).","journal-title":"Npj Parkinsons Dis."},{"key":"1306_CR34","first-page":"a041612","volume":"15","author":"E Bezard","year":"2025","unstructured":"Bezard, E. et al. Modeling Parkinson\u2019s disease in primates. Cold Spring Harb. Perspect. Med. 15, a041612 (2025).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1306_CR35","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2147\/NDT.S139177","volume":"ume 13","author":"H Fujimoto","year":"2017","unstructured":"Fujimoto, H. et al. Brain regions associated with anosognosia for memory disturbance in Alzheimer\u2019s disease: a magnetic resonance imaging study. Neuropsychiatr. Dis. Treat. ume 13, 1753\u20131759 (2017).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"1306_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/01.JGP.0000214541.79965.2d","volume":"14","author":"DY Lee","year":"2006","unstructured":"Lee, D. Y. et al. Frontal dysfunction underlies depressive syndrome in Alzheimer disease: a FDG-PET study. Am. J. Geriatr. Psychiatry 14, 625\u2013628 (2006).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"1306_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1474-9726.2012.00859.x","volume":"11","author":"Y Yuan","year":"2012","unstructured":"Yuan, Y., Chen, Y. P., Boyd-Kirkup, J., Khaitovich, P. & Somel, M. Accelerated aging-related transcriptome changes in the female prefrontal cortex. Aging Cell 11, 894\u2013901 (2012).","journal-title":"Aging Cell"},{"key":"1306_CR38","doi-asserted-by":"publisher","unstructured":"Akdas, S., Yuksel, D. & Yazihan, N. Assessment of the relationship between amino acid status and Parkinson\u2019s disease: a comprehensive review and meta-analysis. Can. J. Neurol. Sci. https:\/\/doi.org\/10.1017\/cjn.2024.310 (2024).","DOI":"10.1017\/cjn.2024.310"},{"key":"1306_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.31083\/j.fbl2802033","volume":"28","author":"MJ Basellini","year":"2023","unstructured":"Basellini, M. J. et al. Pathological pathways and alpha-synuclein in Parkinson\u2019s disease: a view from the periphery. Front. Biosci. 28, 33 (2023).","journal-title":"Front. Biosci."},{"key":"1306_CR40","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e230","volume":"35","author":"J-H Choi","year":"2020","unstructured":"Choi, J.-H. et al. Clinical perspectives of Parkinson\u2019s disease for ophthalmologists, otorhinolaryngologists, cardiologists, dentists, gastroenterologists, urologists, physiatrists, and psychiatrists. J. Korean Med. Sci. 35, e230 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"1306_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1021\/acschemneuro.8b00383","volume":"10","author":"L-Y Ma","year":"2019","unstructured":"Ma, L.-Y. et al. Alpha-synuclein in peripheral tissues in Parkinson\u2019s disease. ACS Chem. Neurosci. 10, 812\u2013823 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"1306_CR42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00702-016-1667-6","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova, N., Padmakumar, C., Lewis, S. J. G. & Chaudhuri, K. R. Parkinson\u2019s: a syndrome rather than a disease? J. Neural Transm. 124, 907\u2013914 (2017).","journal-title":"J. Neural Transm."},{"key":"1306_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2014.10.011","volume":"20","author":"F Gardoni","year":"2015","unstructured":"Gardoni, F. & Di Luca, M. Targeting glutamatergic synapses in Parkinson\u2019s disease. Curr. Opin. Pharmacol. 20, 24\u201328 (2015).","journal-title":"Curr. Opin. Pharmacol."},{"key":"1306_CR44","doi-asserted-by":"publisher","first-page":"111349","DOI":"10.1016\/j.brainresbull.2025.111349","volume":"225","author":"NH Almohmadi","year":"2025","unstructured":"Almohmadi, N. H. et al. Glutamatergic dysfunction in neurodegenerative diseases focusing on Parkinson\u2019s disease: Role of glutamate modulators. Brain Res. Bull. 225, 111349 (2025).","journal-title":"Brain Res. Bull."},{"key":"1306_CR45","doi-asserted-by":"publisher","first-page":"2701526","DOI":"10.1155\/2016\/2701526","volume":"2016","author":"FJ Carvajal","year":"2016","unstructured":"Carvajal, F. J., Mattison, H. A. & Cerpa, W. Role of NMDA receptor-mediated glutamatergic signaling in chronic and acute neuropathologies. Neural Plast. 2016, 2701526 (2016).","journal-title":"Neural Plast."},{"key":"1306_CR46","doi-asserted-by":"publisher","first-page":"106226","DOI":"10.1016\/j.nbd.2023.106226","volume":"184","author":"M Serra","year":"2023","unstructured":"Serra, M. et al. Perturbation of serine enantiomers homeostasis in the striatum of MPTP-lesioned monkeys and mice reflects the extent of dopaminergic midbrain degeneration. Neurobiol. Dis. 184, 106226 (2023).","journal-title":"Neurobiol. Dis."},{"key":"1306_CR47","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0006-8993(96)00915-8","volume":"741","author":"M Gerlach","year":"1996","unstructured":"Gerlach, M. et al. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res. 741, 142\u2013152 (1996).","journal-title":"Brain Res."},{"key":"1306_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0304-3940(88)90292-3","volume":"94","author":"JO Rinne","year":"1988","unstructured":"Rinne, J. O., Halonen, T., Riekkinen, P. J. & Rinne, U. K. Free amino acids in the brain of patients with Parkinson\u2019s disease. Neurosci. Lett. 94, 182\u2013186 (1988).","journal-title":"Neurosci. Lett."},{"key":"1306_CR49","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/j.1471-4159.1983.tb08102.x","volume":"40","author":"TL Perry","year":"1983","unstructured":"Perry, T. L., Javoy-Agid, F., Agid, Y. & Fibiger, H. C. Striatal GABAergic neuronal activity is not reduced in Parkinson\u2019s disease. J. Neurochem. 40, 1120\u20131123 (1983).","journal-title":"J. Neurochem."},{"key":"1306_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ana.410200106","volume":"20","author":"SJ Kish","year":"1986","unstructured":"Kish, S. J. et al. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson\u2019s disease: correlation with striatal dopamine loss. Ann. Neurol. 20, 26\u201331 (1986).","journal-title":"Ann. Neurol."},{"key":"1306_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/srep03730","volume":"4","author":"G Porras","year":"2014","unstructured":"Porras, G. et al. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci. Rep. 4, 3730 (2014).","journal-title":"Sci. Rep."},{"key":"1306_CR52","doi-asserted-by":"publisher","first-page":"9575","DOI":"10.1523\/JNEUROSCI.3465-08.2008","volume":"28","author":"S Boulet","year":"2008","unstructured":"Boulet, S. et al. Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J. Neurosci. 28, 9575\u20139584 (2008).","journal-title":"J. Neurosci."},{"key":"1306_CR53","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3389\/fneur.2018.00806","volume":"9","author":"RL O\u2019Gorman Tuura","year":"2018","unstructured":"O\u2019Gorman Tuura, R. L., Baumann, C. R. & Baumann-Vogel, H. Beyond dopamine: GABA, glutamate, and the axial symptoms of Parkinson disease. Front. Neurol. 9, 806 (2018).","journal-title":"Front. Neurol."},{"key":"1306_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/0166-2236(90)90107-L","volume":"13","author":"GE Alexander","year":"1990","unstructured":"Alexander, G. E. & Crutcher, M. D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13, 266\u2013271 (1990).","journal-title":"Trends Neurosci."},{"key":"1306_CR55","doi-asserted-by":"publisher","first-page":"105429","DOI":"10.1016\/j.nbd.2021.105429","volume":"157","author":"L Andreoli","year":"2021","unstructured":"Andreoli, L., Abbaszadeh, M., Cao, X. & Cenci, M. A. Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of Parkinsonism. Neurobiol. Dis. 157, 105429 (2021).","journal-title":"Neurobiol. Dis."},{"key":"1306_CR56","doi-asserted-by":"crossref","unstructured":"Borroto-Escuela, D. O. et al. Brain dopamine transmission in health and Parkinson\u2019s disease: modulation of synaptic transmission and plasticity through volume transmission and dopamine heteroreceptors. Front. Synaptic Neurosci. 10, 20 (2018).","DOI":"10.3389\/fnsyn.2018.00020"},{"key":"1306_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105263","volume":"25","author":"E Florio","year":"2022","unstructured":"Florio, E. et al. D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia. iScience 25, 105263 (2022).","journal-title":"iScience"},{"key":"1306_CR58","doi-asserted-by":"publisher","first-page":"106278","DOI":"10.1016\/j.nbd.2023.106278","volume":"186","author":"M S\u00e1ez","year":"2023","unstructured":"S\u00e1ez, M. et al. D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse. Neurobiol. Dis. 186, 106278 (2023).","journal-title":"Neurobiol. Dis."},{"key":"1306_CR59","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.1160575","volume":"321","author":"W Shen","year":"2008","unstructured":"Shen, W., Flajolet, M., Greengard, P. & Surmeier, D. J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321, 848\u2013851 (2008).","journal-title":"Science"},{"key":"1306_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0022-510X(97)00069-5","volume":"150","author":"JA Molina","year":"1997","unstructured":"Molina, J. A. et al. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson\u2019s disease. J. Neurol. Sci. 150, 123\u2013127 (1997).","journal-title":"J. Neurol. Sci."},{"key":"1306_CR61","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.clnu.2017.10.009","volume":"37","author":"C Papadia","year":"2018","unstructured":"Papadia, C., Osowska, S., Cynober, L. & Forbes, A. Citrulline in health and disease. Review on human studies. Clin. Nutr. 37, 1823\u20131828 (2018).","journal-title":"Clin. Nutr."},{"key":"1306_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich, M. T., Oertel, W. H., Surmeier, D. J. & Geibl, F. F. Mitochondrial dysfunction in Parkinson\u2019s disease \u2013 a key disease hallmark with therapeutic potential. Mol. Neurodegener. 18, 83 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1306_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41531-022-00370-3","volume":"8","author":"MG Stykel","year":"2022","unstructured":"Stykel, M. G. & Ryan, S. D. Nitrosative stress in Parkinson\u2019s disease. Npj Parkinsons Dis. 8, 104 (2022).","journal-title":"Npj Parkinsons Dis."},{"key":"1306_CR64","doi-asserted-by":"crossref","unstructured":"Huang, H.-Y. et al. Branched-chain amino acids in Parkinson\u2019s disease: molecular mechanisms and therapeutic potential. Int. J. Mol. Sci. 26, 6992 (2025).","DOI":"10.3390\/ijms26146992"},{"key":"1306_CR65","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1039\/C5MB00711A","volume":"12","author":"Anna Wuolikainen","year":"2016","unstructured":"Wuolikainen, A. nna et al. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson\u2019s disease and control subjects. Mol. Biosyst. 12, 1287\u20131298 (2016).","journal-title":"Mol. Biosyst."},{"key":"1306_CR66","doi-asserted-by":"publisher","first-page":"101922","DOI":"10.1016\/j.arr.2023.101922","volume":"87","author":"AA Johnson","year":"2023","unstructured":"Johnson, A. A. & Cuellar, T. L. Glycine and aging: evidence and mechanisms. Ageing Res. Rev. 87, 101922 (2023).","journal-title":"Ageing Res. Rev."},{"key":"1306_CR67","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/bs.apha.2017.08.010","volume":"82","author":"H Wolosker","year":"2018","unstructured":"Wolosker, H. The neurobiology of d-serine signaling. Adv. Pharmacol. 82, 325\u2013348 (2018).","journal-title":"Adv. Pharmacol."},{"key":"1306_CR68","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.tins.2016.09.007","volume":"39","author":"H Wolosker","year":"2016","unstructured":"Wolosker, H., Balu, D. T. & Coyle, J. T. The rise and fall of the d-serine-mediated gliotransmission hypothesis. Trends Neurosci 39, 712\u2013721 (2016).","journal-title":"Trends Neurosci"},{"key":"1306_CR69","doi-asserted-by":"publisher","first-page":"175090","DOI":"10.1016\/j.ejphar.2022.175090","volume":"929","author":"I Frouni","year":"2022","unstructured":"Frouni, I. et al. Effect of glycine transporter 1 inhibition with bitopertin on Parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat. Eur. J. Pharmacol. 929, 175090 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"1306_CR70","doi-asserted-by":"publisher","first-page":"174452","DOI":"10.1016\/j.ejphar.2021.174452","volume":"910","author":"I Frouni","year":"2021","unstructured":"Frouni, I. et al. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and Parkinsonism in the MPTP-lesioned marmoset. Eur. J. Pharmacol. 910, 174452 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"1306_CR71","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1017\/S1461145711001015","volume":"15","author":"E Gelfin","year":"2012","unstructured":"Gelfin, E. et al. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson\u2019s disease. Int. J. Neuropsychopharmacol. 15, 543\u2013549 (2012).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1306_CR72","doi-asserted-by":"publisher","first-page":"16778","DOI":"10.1523\/JNEUROSCI.3041-12.2013","volume":"33","author":"Y Schmitz","year":"2013","unstructured":"Schmitz, Y. et al. Glycine transporter-1 Inhibition promotes striatal axon sprouting via NMDA receptors in dopamine neurons. J. Neurosci. 33, 16778\u201316789 (2013).","journal-title":"J. Neurosci."},{"key":"1306_CR73","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.nicl.2018.03.019","volume":"18","author":"VA Coenen","year":"2018","unstructured":"Coenen, V. A. et al. The anatomy of the human medial forebrain bundle: ventral tegmental area connections to reward-associated subcortical and frontal lobe regions. NeuroImage Clin 18, 770\u2013783 (2018).","journal-title":"NeuroImage Clin"},{"key":"1306_CR74","doi-asserted-by":"publisher","first-page":"110766","DOI":"10.1016\/j.exger.2019.110766","volume":"128","author":"A Picca","year":"2019","unstructured":"Picca, A. et al. Circulating amino acid signature in older people with Parkinson\u2019s disease: a metabolic complement to the EXosomes in PArkiNson Disease (EXPAND) study. Exp. Gerontol. 128, 110766 (2019).","journal-title":"Exp. Gerontol."},{"key":"1306_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e05771","volume":"6","author":"A Delamarre","year":"2020","unstructured":"Delamarre, A. et al. Gastrointestinal and metabolic function in the MPTP-treated macaque model of Parkinson\u2019s disease. Heliyon 6, e05771 (2020).","journal-title":"Heliyon"},{"key":"1306_CR76","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1124\/jpet.103.051714","volume":"306","author":"DS Goldstein","year":"2003","unstructured":"Goldstein, D. S., Li, S.-T., Holmes, C. & Bankiewicz, K. Sympathetic Innervation in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson\u2019s disease. J. Pharmacol. Exp. Ther. 306, 855\u2013860 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1306_CR77","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/metabo10110438","volume":"10","author":"M Scholefield","year":"2020","unstructured":"Scholefield, M. et al. Effects of alterations of post-mortem delay and other tissue-collection variables on metabolite levels in human and rat brain. Metabolites 10, 438 (2020).","journal-title":"Metabolites"},{"key":"1306_CR78","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/diagnostics11071146","volume":"11","author":"A Zissler","year":"2021","unstructured":"Zissler, A. et al. Influencing factors on postmortem protein degradation for PMI estimation: a systematic review. Diagnostics 11, 1146 (2021).","journal-title":"Diagnostics"},{"key":"1306_CR79","doi-asserted-by":"publisher","unstructured":"Dienel, G. A. & Nowak, Jr, T. S. Setting standards for brain collection procedures in metabolomic studies. J. Cereb. Blood Flow Metab. https:\/\/doi.org\/10.1177\/0271678X251314331 (2025).","DOI":"10.1177\/0271678X251314331"},{"key":"1306_CR80","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/10408398.2011.573885","volume":"53","author":"M Virarkar","year":"2013","unstructured":"Virarkar, M., Alappat, L., Bradford, P. G. & Awad, A. B. L-arginine and nitric oxide in CNS function and neurodegenerative diseases. Crit. Rev. Food Sci. Nutr. 53, 1157\u20131167 (2013).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"1306_CR81","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11011-021-00689-5","volume":"36","author":"V Zaman","year":"2021","unstructured":"Zaman, V. et al. Cellular and molecular pathophysiology in the progression of Parkinson\u2019s disease. Metab. Brain Dis. 36, 815\u2013827 (2021).","journal-title":"Metab. Brain Dis."},{"key":"1306_CR82","first-page":"195","volume":"14","author":"J Hami","year":"2015","unstructured":"Hami, J. et al. Effects of L-arginine pre-treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson\u2019s diseases in Balb\/c mice. Iran. J. Neurol. 14, 195\u2013203 (2015).","journal-title":"Iran. J. Neurol."},{"key":"1306_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41531-025-01088-8","volume":"11","author":"E Bezard","year":"2025","unstructured":"Bezard, E. et al. Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson\u2019s disease and ageing research. Npj Parkinsons Dis. 11, 227 (2025).","journal-title":"Npj Parkinsons Dis."},{"key":"1306_CR84","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bbrc.2022.12.037","volume":"641","author":"A Osaki","year":"2023","unstructured":"Osaki, A. et al. Endogenous d-serine exists in the mammalian brain independent of synthesis by serine racemase. Biochem. Biophys. Res. Commun. 641, 186\u2013191 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1306_CR85","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/apm.12987","volume":"127","author":"LJ Holm","year":"2019","unstructured":"Holm, L. J. & Buschard, K. L-serine: a neglected amino acid with a potential therapeutic role in diabetes. APMIS 127, 655\u2013659 (2019).","journal-title":"APMIS"},{"key":"1306_CR86","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1007\/s00018-020-03574-z","volume":"77","author":"G Murtas","year":"2020","unstructured":"Murtas, G., Marcone, G. L., Sacchi, S. & Pollegioni, L. L-serine synthesis via the phosphorylated pathway in humans. Cell. Mol. Life Sci. 77, 5131\u20135148 (2020).","journal-title":"Cell. Mol. Life Sci."},{"key":"1306_CR87","doi-asserted-by":"publisher","first-page":"102773","DOI":"10.1016\/j.pneurobio.2025.102773","volume":"249","author":"S Ringlet","year":"2025","unstructured":"Ringlet, S. et al. Glycine-gated extrasynaptic NMDARs activated during glutamate spillover drive burst firing in nigral dopamine neurons. Prog. Neurobiol. 249, 102773 (2025).","journal-title":"Prog. Neurobiol."},{"key":"1306_CR88","doi-asserted-by":"publisher","unstructured":"Usiello, A. et al. Chiral shift toward D-serine reflects intrathecal inflammation in multiple sclerosis and counteracts motor impairment in a murine model. Preprint at https:\/\/doi.org\/10.1101\/2025.05.07.652561 (2025).","DOI":"10.1101\/2025.05.07.652561"},{"key":"1306_CR89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40035-024-00430-z","volume":"13","author":"K Lau","year":"2024","unstructured":"Lau, K., Kotzur, R. & Richter, F. Blood\u2013brain barrier alterations and their impact on Parkinson\u2019s disease pathogenesis and therapy. Transl. Neurodegener. 13, 37 (2024).","journal-title":"Transl. Neurodegener."},{"key":"1306_CR90","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey, M. G. et al. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 22, 657\u2013673 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1306_CR91","doi-asserted-by":"crossref","unstructured":"Sordillo, L. A., Sordillo M.D., P. P. & Alfano, R. R. Abnormal tryptophan metabolism in Alzheimer\u2019s disease (ALZ): label-free spectroscopy suggests an alternative theory of ALZ causation. In Optical Biopsy XVIII: Toward Real-Time Spectroscopic Imaging and Diagnosis 11234, 135\u2013139 (SPIE, 2020).","DOI":"10.1117\/12.2550309"},{"key":"1306_CR92","doi-asserted-by":"publisher","first-page":"14769","DOI":"10.3390\/ijms241914769","volume":"24","author":"M Ambeskovic","year":"2023","unstructured":"Ambeskovic, M. et al. Metabolomic signatures of Alzheimer\u2019s disease indicate brain region-specific neurodegenerative progression. Int. J. Mol. Sci. 24, 14769 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1306_CR93","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s10072-013-1289-9","volume":"34","author":"MC Gueli","year":"2013","unstructured":"Gueli, M. C. & Taibi, G. Alzheimer\u2019s disease: amino acid levels and brain metabolic status. Neurol. Sci. 34, 1575\u20131579 (2013).","journal-title":"Neurol. Sci."},{"key":"1306_CR94","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-019-0294-x","volume":"16","author":"S Meoni","year":"2020","unstructured":"Meoni, S., Macerollo, A. & Moro, E. Sex differences in movement disorders. Nat. Rev. Neurol. 16, 84\u201396 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1306_CR95","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"1306_CR96","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1306_CR97","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak, H. & Braak, E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol. Aging 16, 271\u2013278 (1995).","journal-title":"Neurobiol. Aging"},{"key":"1306_CR98","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann, G. et al. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34, 939\u2013944 (1984).","journal-title":"Neurology"},{"key":"1306_CR99","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1523\/JNEUROSCI.0610-20.2020","volume":"40","author":"E Bezard","year":"2020","unstructured":"Bezard, E. et al. \u00b5 opioid receptor agonism for L-DOPA-induced dyskinesia in Parkinson\u2019s disease. J. Neurosci. 40, 6812\u20136819 (2020).","journal-title":"J. Neurosci."},{"key":"1306_CR100","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1093\/cercor\/bhu076","volume":"25","author":"M Engeln","year":"2015","unstructured":"Engeln, M., De Deurwaerd\u00e8re, P., Li, Q., Bezard, E. & Fernagut, P.-O. Widespread monoaminergic dysregulation of both motor and non-motor circuits in Parkinsonism and dyskinesia. Cereb. Cortex 25, 2783\u20132792 (2015).","journal-title":"Cereb. Cortex"},{"key":"1306_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-022-00299-7","volume":"8","author":"H Hulme","year":"2022","unstructured":"Hulme, H. et al. Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia. Npj Parkinsons Dis. 8, 1\u201311 (2022).","journal-title":"Npj Parkinsons Dis."},{"key":"1306_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45419-1","volume":"9","author":"T Nuzzo","year":"2019","unstructured":"Nuzzo, T. et al. The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson\u2019s disease patients. Sci. Rep. 9, 8898 (2019).","journal-title":"Sci. Rep."},{"key":"1306_CR103","doi-asserted-by":"publisher","first-page":"e12322","DOI":"10.1371\/journal.pone.0012322","volume":"5","author":"E Santini","year":"2010","unstructured":"Santini, E. et al. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS ONE 5, e12322 (2010).","journal-title":"PLoS ONE"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01306-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:01:46Z","timestamp":1776060106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01306-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01306-x","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}